OBJECTIVE: To evaluate the economy of Xianyu capsules in the treatment of epilepsy. METHODS: Based on a published randomized controlled trial

the decision tree model of treating epilepsy with Xianyu capsules combined with Magnesium valproate sustained-release tablets was constructed from the perspective of health system. The reduction rate of epilepsy before and after treatment was taken as the effect index

and the cost parameters were calculated based on the drug cost and the annual outpatient treatment cost of disease treatment. The economy of Xianyu capsules combined with Magnesium valproate sustained-release tablets compared with magnesium valproate sustained-release tablets alone in the treatment of patients with epilepsy was evaluated. Sensitivity analysis was used to verify the robustness of the results. RESULTS: The cost-effectiveness analysis showed that after 60 d of treatment

the treatment regimen of Xianyu capsules combined with Magnesium valproate sustained-release tablets could significantly reduce the number of epilepsy. The treatment cost of Xianyu capsules combined with Magnesium valproate sustained-release tablets was higher than that of magnesium valproate sustained-release tablets alone

and the effective output was also higher than that of Magnesium valproate sustained-release tablets alone. The incremental cost-effectiveness ratio was 7 051.79 yuan

about 0.22 times of the per capita disposable income of China in 2020. Sensitivity analysis showed that the results of this study were relatively stable. CONCLUSIONS: The willingness to pay threshold of the patients in this study is the per capita disposable income of China in 2020. Under this assumption

Xianyu capsules combined with Magnesium valproate sustained-release tablets is more economical than Magnesium valproate sustained-release tablets alone. Economic evaluation of Xianyu capsules in the treatment of epilepsy is conducive to rational allocation of medical resources and rational use of drugs by clinicians and patients.